Foghorn Therapeutics Inc.
No SEC Form 4 filings for $FHTX in the last 30 days.
See all $FHTX insider activity →Foghorn Therapeutics (FHTX) will halt development of FHD-909 after Phase 1 trial results showed insufficient efficacy, ending collaboration with Eli Lilly. The company will focus on its proprietary pipeline and reduce workforce by 40%. Wedbush downgraded FHTX to Neutral, cutting its price target to $2. FHTX shares closed at $2.02, down 30.82%.
Analysts this week focused on valuation discipline, trimming winners and cutting stalled growth stories. Key moves: Wells Fargo downgraded FS KKR (FSK) to Underweight with a $10 target, citing credit risks. Stifel upgraded STAAR Surgical (STAA) to Buy, raising its target to $31. Deutsche Bank downgraded Commerzbank (CBKG) to Hold. Citizens downgraded Foghorn Therapeutics (FHTX) after a drug trial failure. UBS downgraded Gurit Holding (GURN) to Neutral.
Analysts updated price targets for several companies. Argus raised Accenture's target to $260, Susquehanna cut CSX's to $55, and Rothschild upgraded Abbott Labs to Buy with a $127 target. Other notable changes include Synaptics, Nike, AtriCure, McCormick, Foghorn, Marathon, and Shattuck Labs.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning FHTX (Foghorn Therapeutics Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent FHTX coverage spans financial news, earnings and market movers.
The termination of the Phase 1 program and partnership signals reduced future revenue potential and increased execution risk.
Sharp decline expected to continue as near‑term catalysts are absent.
Foghorn likely faces significant downside.
Neutral rating may curb recent buying momentum.
The downgrade and drug discontinuation remove near‑term catalysts, likely driving the stock lower.
AlphAI scores every news story that mentions FHTX with an AI model for sentiment and relevance, and aggregates insider trades from Foghorn Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Foghorn Therapeutics (FHTX) will halt development of FHD-909 after Phase 1 trial results showed insufficient efficacy, ending collaboration with Eli Lilly. The company will focus on its proprietary pipeline and reduce workforce by 40%. Wedbush downgraded FHTX to Neutral, cutting its price target to $2. FHTX shares closed at $2.02, down 30.82%.
2 min readAnalysts this week focused on valuation discipline, trimming winners and cutting stalled growth stories. Key moves: Wells Fargo downgraded FS KKR (FSK) to Underweight with a $10 target, citing credit risks. Stifel upgraded STAAR Surgical (STAA) to Buy, raising its target to $31. Deutsche Bank downgraded Commerzbank (CBKG) to Hold. Citizens downgraded Foghorn Therapeutics (FHTX) after a drug trial failure. UBS downgraded Gurit Holding (GURN) to Neutral.
2 min readAnalysts updated price targets for several companies. Argus raised Accenture's target to $260, Susquehanna cut CSX's to $55, and Rothschild upgraded Abbott Labs to Buy with a $127 target. Other notable changes include Synaptics, Nike, AtriCure, McCormick, Foghorn, Marathon, and Shattuck Labs.
2 min readAnalysts downgraded several companies: Foghorn Therapeutics (FHTX) to Neutral, First Busey (BUSE) to Neutral with a $30 target, AST SpaceMobile (ASTS) to Neutral with a $65 target, AtriCure (ATRC) to Hold with a $57 target, and Equity Bancshares (EQBK) to Neutral with a $52 target. ASTS closed at $57.04 on Thursday.
2 min readCitizens downgraded Foghorn Therapeutics (FHTX) to Market Perform after it and Eli Lilly discontinued the FHD-909 drug candidate due to poor efficacy. Shares fell 18% to $2.88, extending a 34% YTD decline. Citizens cited lack of near-term catalysts, noting shares trade at a 26% premium to cash reserves. InvestingPro analysis suggests undervaluation, while Stifel lowered its price target to $5.00 but maintained a Buy rating.
2 min readStifel reduced Foghorn Therapeutics' (FHTX) price target to $5.00 from $12.00, citing pipeline shifts. FHTX shares trade at $2.70, down 34% YTD. The company will focus on its wholly owned pipeline, extending cash runway to mid-2029. Stifel values FHTX at $138M net cash by 2026. Citizens reiterated a Market Outperform rating with a $9.00 target.
2 min readU.S. stocks fell Thursday, with the Dow Jones dropping 200 points. Micron (MU) reported Q4 revenue of $54.23B, beating estimates. Nexalin (NXL) and Stablecoin (SDEV) shares surged, while Corteva (CTVA) and NewGenIvf (NIVF) shares declined. Oil and gold prices rose, while European and Asian markets closed mixed.
3 min readFoghorn Therapeutics (FHTX) stock fell 43.7% after discontinuing its lead oncology asset, FHD-909, due to lack of efficacy. The company also ended a collaboration with Eli Lilly and plans a 40% workforce reduction, redirecting resources to its proprietary pipeline. The S&P 500, Dow Jones, and Nasdaq were up slightly, indicating the decline was company-specific.
2 min readFoghorn Therapeutics (FHTX) shares fell 50% premarket after Eli Lilly (LLY) terminated their 2021 collaboration, leading to layoffs. The move followed a review of clinical data.
1 min readFoghorn Therapeutics (FHTX) and Lilly will not advance FHD-909 or the Selective SMARCA2 degrader program. Foghorn will focus on its proprietary pipeline, including EP300 and CBP degraders, and a novel immunology program. The company expects to extend its cash runway into 2H 2029, following a 40% workforce reduction.
2 min read